Mutant IDH1-IN-1 is primarily used in research settings to study and target cancers associated with mutations in the IDH1 gene. It acts as an inhibitor, specifically designed to block the activity of mutant IDH1 enzymes, which are known to produce abnormal metabolites like 2-hydroxyglutarate (2-HG). This compound is valuable in understanding the role of IDH1 mutations in tumor growth and progression, particularly in gliomas and acute myeloid leukemia (AML). Researchers use it to explore potential therapeutic strategies, as inhibiting mutant IDH1 can help restore normal cellular metabolism and reduce cancer cell proliferation. Its application is crucial in developing targeted therapies for patients with IDH1-mutant cancers.